Scientific Sessions 2024  /  New Targets and New Treatments: Advances in Lipid Therapeutics  /  Discussant: CETP inhibition-is it time for a revival?
Logo

American Heart Association

  121
  0

Final ID:

Discussant: CETP inhibition-is it time for a revival?

  • Watson, Karol  ( UCLA , Redondo Beach , California , United States )
    • Author Disclosures:
    KAROL WATSON: DO have relevant financial relationships ; Advisor:amgen:Active (exists now) ; Consultant:novartis:Active (exists now) ; Consultant:boehringer engelheim:Active (exists now)
Meeting Info:

Scientific Sessions 2024

2024

Chicago, Illinois

Session Info:

New Targets and New Treatments: Advances in Lipid Therapeutics

Monday, 11/18/2024 , 01:30PM - 02:45PM

Late-Breaking Science

More abstracts on this topic:
Safety and Efficacy of Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia

Nicholls Stephen, Brunham Liam, Wuerdeman Erin, Neild Annie, Kling Douglas, Hsieh Andrew, Ference Brian, Laufs Ulrich, Banach Maciej, Mehran Roxana, Catapano Alberico, Nelson Adam, Davidson Michael, Ditmarsch Marc, Kastelein John, Ballantyne Christie, Ray Kausik, Navar Ann Marie, Nissen Steven, Goldberg Anne

A Randomized Phase 2 Trial of Muvalaplin: An Oral Disrupter of the Assembly of Lipoprotein(a) Particles

Nicholls Stephen, Ni Wei, Rhodes Grace, Nissen Steven, Navar Ann Marie, Michael Laura, Krege John

More abstracts from these authors:
Don't Let Up: An Ounce of Prevention is Worth a Pound in Cardio-Oncology

Watson Karol, Lloyd-jones Donald

2025 AHA/ACC BP Guideline: The 12 Key Takeaways You Can't Miss

Watson Karol

You have to be authorized to contact abstract author. Please, Login
Not Available